Skip to content

Author

O. Alhalabi

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study

Abstract Background Enfortumab vedotin plus pembrolizumab (EVP) is first-line standard therapy for locally advanced or metastatic urothelial carcinoma (LA/mUC), but real-world pneumonitis incidence and predictors remain poorly characterized. Material and methods We conducted a retrospective cohort study of patients wit...

Luis Angel Diaz Tejada, Fabiana Alexandra Príncipe Osorio, A. Attia et al. · 0 citations
Open access Oct 2026

Skin Toxic Effects and Survival With Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Carcinoma

It is suggested that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.

Zachariah Thomas, Cindy Y. Jiang, Patrick Speck et al. · 0 citations
Review Oct 2026

Rediscovery and conservation assessments of Salvia drusica (Lamiaceae) and Centaurea trachonitica (Asteraceae) in Jabal al Druze, Syria, with lectotypification of both names and the first description of S. drusica nutlet morphology

Field surveys in Jabal al Druze, southern Syria, rediscovered Salvia drusica and Centaurea trachonitica and provided the first modern population-level documentation of both species. We provide updated information on distribution, population size, morphology, habitat, associated flora and threats, together with prelimin...

O. Alhalabi, Ramy Maalouf, E. Véla · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.